LumiGene Inks Reverse Acquisition Pact with Pole Perfect; Dances into Public Market
September 09, 2010
LumiGene Inks Reverse Acquisition Pact with Pole Perfect; Dances into Public Market
Upon completion of the acquisition, the combined company's focus will be strictly on Lumigene's business of developing diagnostics using its nucleic acid amplification platform.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.